Bayban’s Pfizer PFE Stock Holding History

Bayban’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95K	Sell	3,945 -677	-15%	-$17.7K	0.07%	167
2026 Q1	$130K	Buy	4,622 +37	+0.8%	+$985	0.11%	135
2025 Q4	$114K	Buy	+4,585	New	+$116K	0.1%	151

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bayban's PFE Position: Q2 2026 in Review

Bayban reduced its Pfizer (PFE) stake by 15% in Q2 2026, selling an estimated $17.7K and leaving 3,945 shares worth $95K. The position accounts for 0.07% of the portfolio, ranked #167.

Bayban first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $130K in Q1 2026. 2,713 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Bayban held 3,945 shares of Pfizer worth $95K as of Q2 2026.
Bayban sold 677 Pfizer shares in Q2 2026, an estimated $17.7K.
Pfizer made up 0.07% of Bayban's portfolio in Q2 2026, its #167 holding.
Bayban first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
Bayban's Pfizer position peaked at $130K in Q1 2026.
2,713 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.